Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia - Full Text View

Purpose

To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

Condition	Intervention	Phase
Schizophrenia	Drug: Aripiprazole IM Depot	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Aripiprazole

U.S. FDA Resources

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:

The percentage of stable subjects at baseline who remain stable at endpoint. [ Time Frame: Weekly visits for first 4 weeks, then bi-weekly until Week 12, then visits every 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Proportion of subjects meeting exacerbation of psychotic symptoms/impending relapse criteria. [ Time Frame: Bi-weekly for 12 weeks and every 4 weeks for 40 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	1224
Study Start Date:	December 2008
Estimated Study Completion Date:	January 2014
Estimated Primary Completion Date:	July 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Active Treatment of aripiprazole IM depot (300mg or 400mg)	Drug: Aripiprazole IM Depot 300mg or 400mg Other Name: Oral Aripiprazole

Detailed Description:

This will be an open-label, uncontrolled study which will enroll subjects from Phase 4 of Study 31-07-246 and Phase 3 of Study 31- 07-247 and new subjects not participating in Studies 246/247. The treatment history of subjects prior to enrollment in the open-label study will vary according to the design of the pivotal double-blind study (i.e., 31-07-246 or 31-07-247).

This open-label study will be comprised of phases similar to the pivotal double-blind studies (i.e., Studies 246/247): a screening phase (if applicable), a conversion phase (Phase 1, if applicable), an oral stabilization phase (Phase 2), and an IM depot open-label maintenance phase (Phase 3). Phase 3 will be a 52-week treatment period with a 26-week follow-up period.

During Phase 3 (the open-label maintenance phase) oral aripiprazole rescue medication will be allowed for subjects who do not meet stability criteria or meet the criteria for impending relapse/exacerbation of psychotic symptoms.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects who are able to provide written informed consent and/or consent obtained from a legally acceptable representative (as require by IRB/IEC), prior to the initiation of any protocol-required procedures.
Male and female subjects 18 to 65 years of age, inclusive, at time of informed consent.
Subjects who complete Studies 246/247 or who withdrew from the double-blind maintenance phase of either study (Phase 4 of Study 246 or Phase 3 of Study 247), or new subjects not participating in Studies 246/247.
# Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication.
Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications, who can read and understand the written word in order to complete patient-reported outcomes measures, and who can be reliably rated on assessment scales.

Exclusion Criteria:

Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder.
Subjects with schizophrenia that are considered resistant/refractory to antipsychotic treatment by history or response only to clozapine.
Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
Subjects who currently meet DSM-IV-TR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine, or two positive drug screens for cocaine.
Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
Subjects with a history of hypersensitivity to antipsychotic agents.
Subjects with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia at screening.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731549

Show 209 Study Locations

Sponsors and Collaborators

Otsuka Pharmaceutical Development & Commercialization, Inc.

Covance

More Information

No publications provided

Responsible Party:	Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:	NCT00731549 History of Changes
Other Study ID Numbers:	31-08-248
Study First Received:	August 5, 2008
Last Updated:	May 6, 2013
Health Authority:	United States: Food and Drug Administration Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica Australia: TGA - Therapeutic Goods Administration Austria: Federal Office for Safety in Health Care Belgium: Federal Agency for Medicinal Products and Health Products Brazil: CONEP and ANVISA; Bulgaria: Ministry of Health Chile: Instituto de Salud Pública de Chile China: Food and Drug Administration Croatia: Ministry of Health and Social Care Estonia: The State Agency of Medicine Finland: FIMEA - Finnish Medicines Agency France: Ministry of Health Germany: Federal Institute for Drugs and Medical Devices Greece: EOF - The National Organisation for Medicines Hungary: National Institute of Pharmacy India: Drugs Controller General of India Israel: Ministry of Health Malaysia: Ministry of Health Mexico: Comiosion Federal Para la Proteccoin Contra Riesgos Sanitarios Norway: NoMA - Norwegian Medicines Agency Philippines: Department of Health Poland: Ministry of Health Puerto Rico: FDA - Food and Drug Administration Romania: Ministry of Public Health Russia: Pharmacological Committee, Ministry of Health Serbia and Montenegro: Agency for Drugs and Medicinal Devices Slovakia: State Institute for Drug Control South Africa: Medicines Control Council South Korea: Korea Food and Drug Administration (KFDA) Spain: Spanish Agency of Medicines Taiwan: Department of Health Thailand: Food and Drug Administration United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Aripiprazole
IM Depot
Schizophrenia
Intramuscular

Additional relevant MeSH terms:

Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents

Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 23, 2013

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (ASPIRE)